Patients Predicted with Thrombocytopenia Grade I or IV for Whom Dosing Regimens Were Reevaluated According to Toxicity-Prediction Model
| Dosing regimen | ||
| Patient no. | Actual | Proposed |
| 2 | H | H+ |
| 3* | H | L |
| 6 | H | H+ |
| 10 | L | L− |
| 11 | L | L− |
| 12 | H | H+ |
| 15 | L | L− |
| 18 | H | H+ |
| 20 | H | L |
| 21 | H | H+ |
| 23 | L | L− |
| 25* | L | H |
| 28 | L | L− |
| 29 | L | H |
↵* Patient with presence of bone marrow involvement.
H = high-dosing regimen (15 MBq/kg for 90Y-ibritumomab tiuxetan and whole-body dose of 75 cGy with 131I-tositumomab); H+ = increased high-dosing regimen (above 15 MBq/kg for 90Y-ibritumomab tiuxetan and whole-body dose of 75 cGy with 131I-tositumomab); L = low-dosing regimen (11 MBq/kg for 90Y-ibritumomab tiuxetan and whole-body dose of 65 cGy with 131I-tositumomab); L− = reduced low-dosing regimen (below 11 MBq/kg for 90Y-ibritumomab tiuxetan and whole-body dose of 65 cGy with 131I-tositumomab).